- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Despite technical and regulatory hurdles, gene therapy is on its way to becoming a reality. Research and clinical trials have expanded to include cancer, neurological, cardiovascular, and pulmonary disorders, infectious diseases such as AIDS, and monogenic disorders such as cystic fibrosis and hemophilia. Short-term therapy markets such as cancer and cardiovascular disease will probably be the first to reap financial benefits from gene therapy.
Frost & Sullivan's ( http://www.ti.frost.com ) new study, Advances in Gene Therapy, provides an overview of the current developments and advanced technologies in gene therapy, and a complete analysis of the key market drivers, restraints, applications, and trends that impact this field.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the Advances in Gene Therapy, then send an e-mail to Melina Trevino - Corporate Communications at with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.
"The positive results from cancer testing have positioned gene therapy closer to commercial roll-out," says Frost & Sullivan Research Analyst Katherine Austin. "Moreover, the first gene therapy products, already in the late-stage clinical trials, are expected to rely on a short-term effect: for example, the killing of cancer cells through immune stimulation or induction of apoptosis (cellular suicide); or the growth of new blood vessels for the treatment of cardiovascular disease."
Novel innovations in polymer chemistry, nanotechnology, and viral vectors, and an increasing understanding of the biology of exogenous gene expression, expect to overcome the technical obstacles and boost the growth of this technique. In addition, significant advances in recombinant DNA technology and genetic engineering have improved ways to introduce new genes into cells, resulting in the expansion of disease targets for gene therapy beyond traditional genetic diseases to chronic diseases such as diabetes.
However, a number of technical and regulatory hurdles are still prevalent, particularly for long-term gene therapies. To date, only a single human gene-therapy product, Gendicine, for the treatment of cancer in China, has reached the market. The main difficulty in developing clinically useful gene therapies has been in designing safe and efficient delivery systems. Regulatory barriers represent another major hurdle.
"The numerous requirements of the ideal vector include, the need to deliver sufficient quantities of therapeutic DNA into a large number of cells, to express the gene at sufficiently high levels to have an effect on the disease, and to do all this without toxicity," explains Austin. "In addition, regulatory agencies in countries other than China are being extremely cautious, following a number of high profile cases where the gene therapy caused illness or death."
There is still little doubt that scientific ingenuity will eventually overcome the remaining obstacles. Gene therapy now is about where monoclonal antibodies were fifteen years ago, and that market is currently worth over $20 billion a year. If developers can persevere and overcome the technical hurdles, major pharmaceutical companies will collaborate, investors will return, and once a few products prove to be safe, regulatory agencies will ease up.
Advances in Gene Therapy is part of the Technical Insights Subscription, and it thoroughly examines gene-delivery vehicles and technologies, vector design, DNA vaccine design, and clinical status of product candidates. This study also discusses the following markets: cancer, cardiovascular disease, genetic disease, infectious disease, neurological disorders, and other chronic and acute disorders. Interviews are available to the press.
Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective, and combines ongoing analysis of markets, technologies, econometrics, and demographics.
For more information, please click here
Frost & Sullivan
Corporate Communications – North America
Melina Trevino, 210-247-2440
Corporate Communications - Latin America
José María Jantus, + 54-11-4777- 9951
F: + 54-11-4777-0071
Corporate Communications – Europe
Radhika Menon Theodore
Corporate Communications – Asia Pacific
Jasminder Kaur, 65-6890-0937
Corporate Communications – South Asia & Middle East
Shwetha Thomas, +91 22 4001 3429
F: +91 22 2832 4713
Corporate Communications – Australia & New Zealand
Sharmin Jassal, +61 2 8247 8900
F: +61 2 9252 8066
Corporate Communications – China
Amelia Wong, +86 21 5407 5783 Ext 8669
M: +86 13621724823
Corporate Communications – Africa
Patrick Cairns, +27 21 680 3274
F: +27 21 680 3296
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers
Explaining how 2-D materials break at the atomic level January 20th, 2017